The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Farnesyl transferase inhibitor (FTI) darlifarnib (KO-2806) in combination with adagrasib in KRAS G12C mutated (mut) advanced solid tumors: Preliminary results from the FIT-001 phase 1 first-in-human trial.
 
Andrea Zivi
No Relationships to Disclose
 
David Hong
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - Breakthrough Bio; crossbridge Bio; MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Abbvie; Acuta Capital Partners; Alphasights; Amgen; BeiGene; Blueprint Medicines; Boxer Capital; Boxer Capital; Clearview Oncology; COR2ed; EcoR1 Capital; Erasca, Inc; Gerson Lehrman Group; Guidepoint Pharmacy; Immunogenesis; Kestrel Therapeutics; Medscape; Morgan Stanley; Nextech Invest; Pfizer; PharmaResearch; Revolution Medicines; Sequenom; T-Knife; WebMD
Research Funding - Abbvie (Inst); Acendo; Adaptimmune; Adlai Nortye; Alterome Therapeutics; Amgen (Inst); Arvinas; AstraZeneca; Bayer (Inst); BeiGene; BioBridge (Inst); Bristol Myers Squibb (Inst); Deciphera Pharmaceuticals Inc. (Inst); Endeavor BioMedicines; Erasca, Inc; Exelixis (Inst); Genentech; Genentech (Inst); Immunogenesis; InhibRx; KumQuat; Kura Oncology; Lilly; Merck Sharp & Dohme LLC (Inst); National Cancer Institute; Novartis; Pfizer (Inst); Quanta Therapeutics (Inst); Revolution Medicines; Roche; ST Cube; Velavagio; Verastem; VM Pharma
Travel, Accommodations, Expenses - AACR; ImmunoGenesis; Medscape; Telperian
 
Manish Patel
Leadership - ION Pharma
Consulting or Advisory Role - Accutar Biotech; Daiichi Sankyo/UCB Japan; Johnson & Johnson/Janssen; Kura Oncology; Mitsubishi Tanabe Pharma; shivanka Research
Research Funding - Abbvie (Inst); Abdera Thereapeutics (Inst); Accutar Biotech (Inst); Adagene (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Apollo (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avenzo (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Cullinan Oncology (Inst); cyteir (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Georgiamune (Inst); Hotspot Therapeutics (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Incyte (Inst); Janssen (Inst); Kineta (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); Medlink (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); nurix (Inst); Olema Oncology (Inst); OnCusp Therapeutics (Inst); Pfizer (Inst); Prelude Therapeutics (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Sutro Biopharma (Inst); Syndax (Inst); Systimmune (Inst); TeneoBio (Inst); Vividion Therapeutics (Inst); Zai Lab (Inst); Zymeworks (Inst)
 
Jacob Thomas
Consulting or Advisory Role - Conjupro Biotherapeutics; Kura Oncology
 
Justine Yang Bruce
Stock and Other Ownership Interests - ImageMoverMD (I)
Consulting or Advisory Role - Coherus Biosciences; GlaxoSmithKline; Kura Oncology; Lilly; Merck; Merus NV
Research Funding - Astellas Pharma (Inst); Bicara Therapeutics (Inst); Incyte (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
 
Sanjay Goel
No Relationships to Disclose
 
Glenn Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Massachusetts Medical Society
Consulting or Advisory Role - Adela; Astellas Pharma; AstraZeneca; Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Coherus Biosciences; Coherus Biosciences; CorriXr; Curie.Bio; Elevar Therapeutics; Grey Wolf Therapeutics; Guardian Bio; InhibRx; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Nextech Invest; OncoSwitch; Ottimo; Outrun; PDS Biotechnology; Pyxis; Regeneron; Remix Therapeutics; Replimune; Rgenta; Surface Oncology; TD Cowan; Tubulis GmbH
Research Funding - Actuate Therapeutics (Inst); Adenoid Cystic Carcinoma Research Foundation (Inst); ASCO (Inst); Astellas Pharma (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Cellestia Biotech (Inst); Coherus Biosciences (Inst); Exelixis (Inst); Gateway for Cancer Research; Genentech (Inst); ImmunityBio (Inst); KSQ Therapeutics (Inst); Kura Oncology (Inst); PHASE ONE Foundation (Inst); Regeneron (Inst); Remix Therapeutics (Inst); Rgenta (Inst); Secura Bio (Inst); Secura Bio (Inst)
Other Relationship - Tubulis GmbH
 
Jacques Medioni
Consulting or Advisory Role - Daiichy Sankyo; Gilead Sciences
Travel, Accommodations, Expenses - Novartis; Pfizer/Lilly
 
Stefania Salvagni
Travel, Accommodations, Expenses - BeiGene
 
Susanna Ulahannan
Consulting or Advisory Role - ASCO
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); ArQule (Inst); artios (Inst); Artios (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); Eisai (Inst); Erasca, Inc (Inst); evelo biosciences (Inst); Exelixis (Inst); Exelixis (Inst); Exthera medical (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); immunitas (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); Omega Therapeutics (Inst); OncoMed (Inst); Pfizer (Inst); Pionyr (Inst); Purple Biotech (Inst); Qurgen (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sapience Therapeutics (Inst); Synermore biologics (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); Tesaro (Inst); Theradex (Inst); Totus Medicines (Inst); Tvardi Therapeutics (Inst); Tvardi Therapeutics (Inst); Vigeo Therapeutics (Inst)
 
Andrew Hendifar
Consulting or Advisory Role - Alcresta Therapeutics; Amgen; Curium Pharma; Exelixis; Faraday Pharmaceuticals; Ipsen; Merck; Novartis; Pancreatic Cancer Action Network; Pfizer; Regeneron; Valar Labs
Research Funding - Ipsen; NGM Biopharmaceuticals (Inst)
Travel, Accommodations, Expenses - Halozyme
Other Relationship - Rayzebio
 
Douglas Laux
No Relationships to Disclose
 
Guzman Alonso
Consulting or Advisory Role - Boehringer Ingelheim; Ellipses Pharma
Travel, Accommodations, Expenses - Ellipses Pharma
 
Aurore Vozy
Consulting or Advisory Role - Merck Serono; MSD Oncology
 
Ramon Yarza
Travel, Accommodations, Expenses - BioNTech; Boehringer Ingelheim; Kura Oncology; Merck
Other Relationship - Principal Investigator duties for institutional funding: AbbVie (Inst); Principal Investigator duties for institutional funding: Ascendis Pharma (Inst); Principal Investigator duties for institutional funding: Bayer (Inst); Principal Investigator duties for institutional funding: BioNTech (Inst); Principal Investigator duties for institutional funding: Boehringer Ingelheim (Inst); Principal Investigator duties for institutional funding: Bristol Myers Squibb (Inst); Principal Investigator duties for institutional funding: Daiichi Sankyo (Inst); Principal Investigator duties for institutional funding: Debiopharm (Inst); Principal Investigator duties for institutional funding: Eikon Therapeutics (Inst); Principal Investigator duties for institutional funding: GSK (Inst); Principal Investigator duties for institutional funding: Kumquat (Inst); Principal Investigator duties for institutional funding: Kura Oncology (Inst); Principal Investigator duties for institutional funding: Merck (Inst); Principal Investigator duties for institutional funding: Novartis (Inst); Principal Investigator duties for institutional funding: Nuvalent (Inst); Principal Investigator duties for institutional funding: OnKure (Inst); Principal Investigator duties for institutional funding: Pfizer (Inst); Principal Investigator duties for institutional funding: Pierre Fabre (Inst); Principal Investigator duties for institutional funding: Pyxis Oncology (Inst); Principal Investigator duties for institutional funding: Seagen (Inst)
 
Tuan Anh Tran
Employment - Kura Oncology
Stock and Other Ownership Interests - Arrivent BioPharma; Ascendis Pharma (unexercised warrants); Crinetics Pharmaceuticals; Kura Oncology; Novocure; Petros Pharmaceuticals; Recursion Therapeutics; Summit Therapeutics
 
Jenchun Kuan
Employment - Kura Oncology
Stock and Other Ownership Interests - Kura Oncology
 
Binaifer Balsara
Employment - Kura Oncology
 
Jabed Seraj
Employment - Kura Oncology
 
Vanesa Gregorc
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo; Pierre Fabre; Regeneron
Travel, Accommodations, Expenses - Genfleet Therapeutics; MSD; Pierre Fabre